Journal article
Continuous integrated manufacturing of therapeutic proteins.
- Karst DJ Institute for Chemical and Bioengineering, Department for Chemistry and Applied Biosciences, ETH Zurich, Switzerland.
- Steinebach F Institute for Chemical and Bioengineering, Department for Chemistry and Applied Biosciences, ETH Zurich, Switzerland.
- Morbidelli M Institute for Chemical and Bioengineering, Department for Chemistry and Applied Biosciences, ETH Zurich, Switzerland. Electronic address: massimo.morbidelli@chem.ethz.ch.
- 2018-01-01
Published in:
- Current opinion in biotechnology. - 2018
English
With the growth of our understanding of biopharmaceutical processes, a transition from classical batch to continuous integrated manufacturing of therapeutic proteins is taking place across laboratory, clinical and commercial scales. Encouraged by regulatory authorities, this transition is favoured by new emerging technologies as well as by the development of better simulation models. The current status of continuous cell culture and downstream processes and requirements for their successful integration are discussed in this article, with specific reference to product quality attributes.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.copbio.2017.12.015
- PMID 29289800
- Persistent URL
- https://sonar.ch/global/documents/155046
Statistics
Document views: 27
File downloads: